Normal cerebrospinal fluid levels of hypocretin-1 (orexin A) in patients with fibromyalgia syndrome

Sleep Medicine

Volumn 8, Issue 3, 2007, Pages 260-265

  Taiwo, Oludare B ^a   Russell, I Jon ^b   Mignot, Emmanuel ^c   Lin, Ling ^c   Michalek, Joel E ^b   Haynes, Wanda ^b   Xiao, Yangming ^b   Zeitzer, Jamie M ^c   Larson, Alice A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Stanford Medicine Children s Health   (United States)

Author keywords

Clinical trial; CSF; Fibromyalgia; Hypocretin 1; Orexin A; Sleep

Indexed keywords

OREXIN A;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; FATIGUE; FEMALE; FIBROMYALGIA; HUMAN; INSOMNIA; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; AGED; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; FIBROMYALGIA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROPEPTIDES; RADIOIMMUNOASSAY; REFERENCE VALUES; SLEEP, REM; STATISTICS;

EID: 33947689212     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2006.08.015     Document Type: Article

References (42)

1. Sarzi-Puttini P., Rizzi M., Andreoli A., et al. Hypersomnolence in fibromyalgia syndrome. Clin Exp Rheumatol 20 (2002) 69-72
2. Wolfe F., Ross K., Anderson J., et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 (1995) 19-28
3. Wolfe F., Hawley D.J., and Wilson K. The prevalence and meaning of fatigue in rheumatic disease. Source J Rheumatol 23 (1996) 1407-1417
4. Disdier P., Genton P., Bolla G., et al. Clinical screening for narcolepsy/cataplexy in patients with fibromyalgia. Clin Rheumatol 13 (1994) 132-134
5. Dauvilliers Y., and Touchon J. Sleep in fibromyalgia: review of clinical and polysomnographic data. Neurophysiol Clin 31 (2001) 18-33
6. Moldofsky H., Scarisbrick P., England R., and Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 37 (1975) 341-351
7. Moldofsky H.K. Disordered sleep in fibromyalgia and related myofascial facial pain conditions. Dent Clin North Am 45 (2001) 701-713
8. Mahowald M.L., and Mahowald M.W. Nighttime sleep and daytime functioning (sleepiness and fatigue) in less well-defined chronic rheumatic diseases with particular reference to the 'alpha-delta NREM sleep anomaly. Sleep Med 1 (2000) 195-207
9. Carette S., Oakson G., Guimont C., and Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis and Rheumatism 38 (1995) 1211-1217
10. Affleck G., Urrows S., Tennen H., Higgins P., and Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain 68 (1996) 363-368
11. Nicassio P.M., Moxham E.G., Schuman C.E., and Gevirtz R.N. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain 100 (2002) 271-279
12. Klerman E.B., Goldenberg D.L., Brown E.N., et al. Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 86 (2001) 1034-1039
13. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000) 39-40
14. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000) 991-997
15. Thannickal T.C., Moore R.Y., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
16. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59 (2002) 1553-1562
17. Taheri S., Zeitzer J.M., and Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Ann Rev Neurosci 25 (2002) 283-313
18. Grudt T.J., van den Pol A.N., and Perl E.R. Hypocretin-2 (orexin-B) modulation of superficial dorsal horn activity in rat. J Physiol 538 (2002) 517-525
19. Yamamoto T., Nozaki-Taguchi N., and Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br J Pharmacol 137 (2002) 170-176
20. Bingham S., Davey P.T., Babbs A.J., et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92 (2001) 81-90
21. Cheng J.K., Chou R.C., Hwang L.L., and Chiou L.C. Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain. J Pharmacol Exp Ther 307 (2003) 1065-1071
22. Yamanaka A., Muraki Y., Tsujino N., et al. Regulation of orexin neurons by the monoaminergic and cholinergic systems. Biochem Biophys Res Commun 303 (2003) 120-129
23. Suyama H., Kawamoto M., Shiraishi S., et al. Analgesic effect of intrathecal administration of orexin on neuropathic pain in rats. In Vivo 18 (2004) 119-123
24. Peyron C., Tighe D.K., van Den Pol A.N., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18 (1998) 9996-10015
25. van Den Pol A.N. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci 19 (1999) 3171-3182
26. Catley D., Kaell A.T., Kirschbaum C., and Stone A.A. A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. Arthritis Care Res 13 (2000) 51-61
27. Torpy D.J., Papanicolaou D.A., Lotsikas A.J., et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Curr Rheumatol 4 (2000) 299-305
28. Neeck G., and Crofford J.L. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 26 (2000) 989-1002
29. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol 4 (2002) 299-305
30. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology criteria for the classification of fibromyalgia. Arthritis Rheum 33 (1990) 160-172
31. Russell I.J., Michalek J.E., Xiao Y., et al. Therapy with a central alpha-2-agonist [tizanidine] decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome. Arthritis Rheum 46 (2002) S614
32. Salomon R.M., Ripley B., Kennedy J.S., et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry 54 (2003) 96-104
33. Russell I.J., Orr M.D., Littman B., et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37 (1994) 1593-1601
34. Jenkins C.D., Stanton B.A., Niemcryk S.J., and Rose R.M. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 41 (1988) 313-321
35. Burckhardt C.S., Clark S.R., and Bennett R.M. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18 (1991) 728-733
36. Fries J.F., Spitz P., and Young D.Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9 (1982) 789-793
37. Zung W.W.K., and Durham N.C. A self-rating depression scale. Arch Gen Psychiatry 12 (1965) 63-70
38. Zung W.W.K. The measurement of affects: depression and anxiety. Mod Probl Pharmacopsychiatry 7 (1974) 170-188
39. Russell I.J., Fletcher E.M., Michalek J.E., et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 34 (1991) 552-560
40. Yoshida Y., Fujiki N., Nakajima T., et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14 (2001) 1075-1081
41. Wu M.F., John J., Maidment N., et al. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol 283 (2002) 1079-1086
42. Zeitzer J.M., Buckmaster C.L., Parker K.J., et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 23 (2003) 3555-3560